ZMYND19

Across TCGA pan-cancer cohorts, ZMYND19 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of ZMYND19’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ZMYND19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZMYND19 is over-expressed in tumor.

COAD, HNSC, and BLCA are the cancer types where ZMYND19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZMYND19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+1.760	<.001	12	view →
HNSC	Male	IV	+1.513	<.001	11	view →
BLCA	Male	All	+1.398	<.001	11	view →
LUAD	Male	III,IV	+0.988	<.001	11	view →
STAD	Male	III,IV	+1.403	<.001	10	view →
LIHC	Female	II,III,IV	+1.191	<.001	9	view →
LUSC	All	III,IV	+1.780	<.001	8	view →
KIRP	All	III,IV	+0.854	<.001	8	view →
READ	All	All	+1.327	<.001	7	view →
UCEC	All	All	+0.879	<.001	6	view →
BRCA	All	III,IV	+0.797	<.001	6	view →
KIRC	Female	All	+0.387	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

ZMYND19–COAD

Open the COAD breakdown →